US OptionsDetailed Quotes

ADPT241220P7500

Watchlist
  • 0.00
  • 0.000.00%
15min DelayClose Dec 20 09:30 ET
0.00High0.00Low
Intraday
  • 5D
  • Daily

No Data

News

Comments

    This_Guy
    This_Guy
    Dec 8 17:28
    $Nektar Therapeutics (NKTR.US)$
    Nektar Therapeutics Announces NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients with Relapsed or Refractory Large B-cell Lymphoma at the 66th Annual ASH Meeting
    Positive
    73% complete response rate at 6 months vs 50% for placebo
    5.8-fold improvement in CD8+ CAR-T cell kinetics compared to placebo
    Two patients converted from partial to complete response with NKTR-255
    Results exceeded historical benchmark data of 41-44% comple...
    This_Guy
    This_Guy
    Dec 8 17:27
    $Adaptive Biotechnologies (ADPT.US)$
    Adaptive Biotechnologies Announces New Data at the 66th ASH Annual Meeting Highlighting Advances in MRD Testing with clonoSEQ® and Its Impact on Blood Cancer Treatment Decisions
    Positive
    Phase 3 trial data shows clonoSEQ can help avoid unnecessary transplantation procedures in MCL patients
    FELIX study demonstrated 84% treatment response rate with MRD <10⁻⁶
    Evidence supports clonoSEQ's effectiveness in early detection of disease progression
    Data validates test'...
    Jaguar8
    Jaguar8
    Dec 8 16:19
    NEWS SATURDAY 12/7
    $Adaptive Biotechnologies (ADPT.US)$
    Adaptive Biotechnologies Announces New Data at the 66th ASH Annual Meeting Highlighting Advances in MRD Testing with clonoSEQ® and Its Impact on Blood Cancer Treatment Decisions
    Adaptive Biotechnologies (ADPT) presented new data at the 66th ASH Annual Meeting showcasing the effectiveness of their clonoSEQ® test in measuring residual disease (MRD) for blood cancer treatment. Key findings from multiple studies demonstrate that achieving MRD lev...
    Jaguar8
    Jaguar8
    Aug 29 07:03
    NEWS
    $Adaptive Biotechnologies (ADPT.US)$
    Adaptive Announces IVDR Certification for clonoSEQ® in European Union
    Adaptive Biotechnologies (Nasdaq: ADPT) has announced that its clonoSEQ® test has received In Vitro Diagnostic Regulation (IVDR) 2017/746 Class C certification in the European Union. This makes clonoSEQ the first IVDR-certified test for detecting minimal residual disease (MRD) in patients with lymphoid malignancies. The certification allows for broad use in assessing MRD status and chang...
    2
    TechWhiz
    TechWhiz
    Jun 28 18:55
    Good volume move up.  Small caps like adaptive biotechnologies are moving after Nvidia and other big techs took a break.
    Should see higher prices from here.
Read more